In an exciting leap forward for scientific innovation and medical progress, LSU Health Shreveport proudly announces the acquisition of five new patents by faculty members, both current and retired, during fiscal year 2024 (July 2023-June 2024). These patents not only safeguard the intellectual property of their creators but also introduce fresh approaches to treatment and processes that push the boundaries of science and healthcare.
Obtaining a patent is more than just a legal milestone; it’s a testament to the ingenuity, creativity, and dedication of each inventor and their team. It reflects LSU Health Shreveport’s dedication to nurturing innovation and discovery. The journey from idea to patent issuance is lengthy and complex, spanning years of rigorous research and development. The recently awarded patents, filed between 2017 and 2021, cover a range of utility and divisional patents, ensuring protection for a diverse set of groundbreaking inventions.
Let’s explore these remarkable patents in more detail:
Methods of Treating Neurodegenerative Disorders
Patent Title: Methods of treating neurodegenerative disorders
Inventors: Yuping Wang, MD, PhD, and Xiao-Hong Lu, PhD
Patent Number: US-11707491 (Utility Patent)
Overview: This innovative therapy offers a new approach to addressing neurodegenerative disorders and brain injuries. By utilizing neural progenitor cells from the mammalian placenta, the treatment holds promise for conditions like cerebral palsy, Alzheimer’s, and Parkinson’s disease. Unlike traditional methods, this therapy aims to repair damaged neural tissue directly, providing a novel path to recovery.
Targeting the TLK1/NEK1 Axis in Prostate Cancer
Patent Title: Targeting the TLK1/NEK1 axis in prostate cancer
Inventors: Arrigo De Benedetti, PhD, et al.
Patent Number: US-11826369 (Utility Patent)
Overview: Prostate cancer remains a significant health concern globally. This novel therapy combines with existing treatments to improve their effectiveness and delay disease progression, offering hope to patients facing this challenging diagnosis.
Cancer Treatment via Repositioned Tricyclic Anti-depressant-like Drugs
Patent Title: Cancer treatment via repositioned tricyclic anti-depressant-like drugs as anti-cancer agents
Inventors: James A. Cardelli, PhD, et al.
Patent Number: US-11744827 (Divisional)
Overview: This approach targets the invasion of tumors, particularly in brain cancer, offering a promising avenue for slowing disease progression and reducing mortality.
Method, Device, and System for Bone Fixation
Patent Title: Method, device, and system for bone fixation
Inventors: Giovanni F. Solitro, PhD; R. Shane Barton, MD, MPH, FAAOS, FAOA; and J. Steven Alexander, PhD
Patent Number: US-11806025 (Utility Patent)
Overview: A groundbreaking surgical tool simplifies bone surgeries in animal models, enhancing precision and reproducibility for researchers and surgeons.
Treatment for Methamphetamine Cardiovascular Disease
Patent Title: Treatment for methamphetamine cardiovascular disease
Inventors: Chris G. Kevil, PhD, and Gopi Kolluru, PhD
Patent Number: US-11883426 (Utility Patent)
Overview: This innovative treatment addresses the cardiovascular effects of methamphetamine abuse, offering hope for patients suffering from related complications.
For more information on these pioneering patents and collaborative opportunities with LSU Health Shreveport, please contact the Office for Technology Transfer at techtransfer@lsuhs.edu. These patents underscore LSU Health Shreveport’s commitment to advancing healthcare through innovation and discovery.